Table 1.
Detection of CSCs in established breast cancer cell lines.
| Cell line | Percentage | Method | Reference |
|---|---|---|---|
| BT-474 | 0.5% | SP (H33342 labeling) | [16] |
| EFM-19 | 0.3% | SP (H33342 labeling) | [16] |
| KPL-1 | 8.4% | SP (H33342 labeling) | [16] |
| MCF-7 | 0.8% | SP (H33342 labeling) | [16] |
| UACC-893 | 20% | SP (H33342 labeling) | [16] |
| BT-20 | 5.8% | SP (H33342 labeling) | [16] |
| Cal-51 | 0.8–2% | SP (H33342 labeling) | [16] |
| MCF-7 | 2.4 ± 0.4% | SP (H33342 labeling) | [17] |
| MCF-7 | 1.5% | SP (H33342 labeling) | [18] |
| T47D, | 0% | SP (H33342 labeling) | [17] |
| SK-BR-3 | 0% | SP (H33342 labeling) | [17] |
| MDA-MB-231 | 0% | SP (H33342 labeling) | [17] |
| MDA-MB-231 | 0.1% | SP (H33342 labeling) | [18] |
| MDA-MB-231 | >90% | CD44pos/CD24neg/low (flow cytometry) | [19] |
| MCF-7 | 1.6% (monolayer cultures) 40.3% (mammospheres) |
CD44pos/CD24neg/low (flow cytometry) | [20] |
| MCF-7 | <2% (monolayer cultures) ~50% (mammospheres) | CD44pos/CD24neg/low (flow cytometry) | [21] |
| MCF-7 | 3.5% | SP (H33342 labeling) | [22] |